Small Specialty Pharma Merus Reviews Strategy Amid Sector Woes
Executive Summary
Canada’s Merus Labs has recruited Rothschild & Co to review its business strategy, as much larger companies in the specialty market sector retrench with asset sales and job cuts.
You may also be interested in...
Norgine Builds Specialty Business In Europe From Canada's Merus Labs
Merus Labs' portfolio of well-established products are mainly marketed in Europe, and will drive the growth and diversification of Norgine’s specialty business in the region.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Perrigo 'Unlocks Value' But Weak 2017 Outlook Impedes Revelry
Perrigo bows to pressure from activist investor to 'unlock value' by selling Tysabri royalty stream and laying off 750 staff, but still provides a weak outlook for 2017, prompting analysts to question the wisdom of the strategy.